Horny goat weed is a traditional herbal ingredient derived mainly from species of the Epimedium plant genus, which are native to parts of Asia. Several Epimedium species have been used in traditional Chinese medicine for centuries, where preparations have been associated with sexual health, vitality, and general wellness. The leaves are the primary plant material used in supplements, although the chemical composition can vary between species and extracts.

Horny Goat Weed Overview

Icariin is one of the best-known flavonoids in horny goat weed and is often used as a marker compound when studying standardized extracts. Other constituents include flavonoid glycosides, polysaccharides, and related plant compounds. The amount of icariin and other active constituents can differ substantially between commercial products, depending on the Epimedium species, extraction method, and degree of standardization.

Horny Goat Weed and Sexual Health

Horny goat weed has attracted scientific interest because laboratory research suggests that some of its compounds may influence biological pathways involved in sexual function. In particular, icariin has been investigated for possible effects related to nitric oxide signaling, vascular function, and phosphodiesterase type 5 (PDE5) activity.

Research into horny goat weed for erectile dysfunction does not establish that traditional use translates directly into a clinical treatment effect. Human studies are more limited than laboratory research, and differences in extract composition make results difficult to compare.

Potential areas investigated in research include:

• Erectile response and penile blood flow
• Nitric oxide-related signaling
• Vascular relaxation
• Sexual function and libido
• Hormonal and reproductive parameters
• Antioxidant and cellular effects

Why Horny Goat Weed Is Studied

The proposed connection between horny goat weed and erectile function is mainly based on its potential effects on vascular and signaling pathways involved in erection. An erection depends on adequate blood flow, functioning vascular tissue, nerve signaling, and coordinated smooth-muscle relaxation, which has made these mechanisms relevant targets for research.

Horny goat weed is an active herbal ingredient with promising laboratory findings and clinical evidence base for male sexual health. Clinical studies are therefore important for determining whether the effects observed in experimental models produce meaningful improvements in men with erectile dysfunction.

Mechanism of Action and Claimed Benefits of Horny Goat Weed

Potential Effects on Nitric Oxide Signaling

The proposed mechanism of horny goat weed for erectile dysfunction centers on its potential influence on nitric oxide and cyclic guanosine monophosphate (cGMP) signaling. Nitric oxide plays an important role in erectile physiology because it promotes relaxation of smooth muscle in penile blood vessels and erectile tissue. This relaxation allows increased blood flow, which is necessary for achieving and maintaining an erection.

Icariin, a flavonoid found in Epimedium species, has been investigated for its ability to influence this pathway in experimental models. Laboratory studies suggest that icariin may increase nitric oxide-related signaling and support smooth-muscle relaxation, although these effects observed in laboratory settings cannot be assumed to produce the same response in humans.

Possible PDE5-Related Activity

Researchers have also examined whether icariin can affect phosphodiesterase type 5 (PDE5), an enzyme involved in the breakdown of cGMP. PDE5 inhibition increases the availability of cGMP and is an established mechanism used by prescription erectile dysfunction medicines such as sildenafil.

Experimental research indicates that icariin may have PDE5-inhibitory activity, but its potency appears substantially different from that of established pharmaceutical PDE5 inhibitors. Therefore, findings from laboratory experiments should not be interpreted as evidence that horny goat weed provides an equivalent clinical effect.

Other Proposed Effects

Horny goat weed extracts have also been studied for potential antioxidant, vascular, and cellular effects that could indirectly relate to sexual function. These effects may be relevant because vascular health contributes to normal erectile function.

Research has explored several possible biological actions:

• Supporting nitric oxide production and signaling
• Promoting vascular smooth-muscle relaxation
• Modulating PDE5-related activity
• Supporting endothelial function
• Providing antioxidant activity
• Influencing reproductive and hormonal pathways in experimental models

Claimed Benefits for Erectile Function

Based on these proposed mechanisms, horny goat weed is commonly marketed as an ingredient that may support sexual desire, erectile response, and overall male sexual function. However, marketing claims are broader than the available clinical evidence, and the effects of different Epimedium extracts cannot necessarily be considered equivalent.

Horny goat weed, particularly its icariin content, has been investigated for effects on nitric oxide signaling, cGMP, PDE5 activity, and vascular function, but laboratory mechanisms do not by themselves establish clinical effectiveness for erectile dysfunction.

Why Horny Goat Weed Is Studied for Erectile Dysfunction Treatment

Connection Between Vascular Function and Erectile Function

Horny goat weed has been studied for erectile dysfunction because normal erections depend on adequate blood flow and relaxation of smooth muscle within penile tissue. Erectile dysfunction can involve vascular, neurological, hormonal, psychological, and medication-related factors, but impaired endothelial function and reduced blood flow are important contributors in many men.

Researchers have therefore examined whether compounds in Epimedium extracts can influence pathways that regulate vascular relaxation. Icariin has received particular attention because experimental studies suggest that it may affect nitric oxide signaling and other processes involved in vascular function.

Interest in Icariin

Icariin is one of the main bioactive flavonoids investigated as a possible contributor to the effects attributed to horny goat weed. Researchers have evaluated icariin in laboratory and animal models to determine whether it can influence erectile responses, smooth-muscle relaxation, and signaling pathways associated with penile blood flow.

Its reported PDE5-related activity has also contributed to scientific interest in horny goat weed for erectile dysfunction. PDE5 regulates cGMP, a signaling molecule that contributes to smooth-muscle relaxation during sexual stimulation. This pathway is already an established target for several pharmaceutical treatments for erectile dysfunction.

What Researchers Aim to Determine

Clinical research is needed to determine whether the biological activity observed with icariin or Epimedium extracts produces measurable improvements in men with erectile dysfunction. Studies may examine outcomes such as erectile function scores, erection quality, sexual satisfaction, and related measures of sexual performance.

Research may focus on several questions:

• Does horny goat weed improve erectile function compared with placebo?
• Do standardized extracts produce more consistent effects?
• Does icariin concentration affect clinical outcomes?
• Can treatment influence subjective sexual satisfaction?
• Are effects maintained during longer-term use?
• What adverse effects occur at studied doses?

Importance of Clinical Evidence

The reason for studying horny goat weed is therefore based primarily on plausible biological mechanisms and preclinical findings rather than established clinical effectiveness. Traditional use and laboratory evidence can provide a rationale for human research, but controlled clinical trials are necessary to determine whether these proposed effects are meaningful for people with erectile dysfunction.

Horny goat weed is studied for erectile dysfunction because icariin may influence nitric oxide, cGMP, PDE5-related activity, and vascular function, while clinical research must determine whether these mechanisms translate into measurable improvements in erectile function.

How Studies of Horny Goat Weed Are Designed and Measured

Clinical Study Design

Clinical studies of horny goat weed for erectile dysfunction need to determine whether the ingredient produces measurable effects beyond those associated with placebo treatment. Randomized, placebo-controlled trials provide useful evidence because participants are assigned to different treatment groups and researchers can compare changes over the study period.

Researchers may use standardized Epimedium extracts or preparations containing specified amounts of icariin to improve consistency between participants. Study duration, dosage, extract composition, participant characteristics, and treatment protocols can vary, which makes direct comparison between studies difficult.

Participant Selection

Studies may recruit adult men who report erectile difficulties, with researchers using medical history, questionnaires, or clinical assessments to characterize their symptoms. Researchers can also establish eligibility criteria to exclude factors that could interfere with interpretation, such as certain medications or medical conditions.

Important study characteristics may include:

• Participant age and baseline erectile function
• Severity and duration of erectile dysfunction
• Presence of cardiovascular or metabolic risk factors
• Medication and supplement use
• Dose and chemical standardization of the horny goat weed preparation
• Length of treatment and follow-up

Measuring Erectile Function

Validated questionnaires are commonly used to measure changes in erectile function and related aspects of sexual health. The International Index of Erectile Function (IIEF) is one established assessment tool and includes questions covering erectile function, orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction.

Researchers may also record changes in erection frequency, erection quality, successful intercourse, or patient-reported treatment satisfaction. Some experimental studies can use physiological measurements, although these methods are less common in routine clinical research.

Interpreting Study Outcomes

A meaningful clinical study should compare changes from baseline between the horny goat weed and control groups rather than relying only on changes within the treatment group. Researchers may report statistical significance, effect size, adverse events, and changes in individual domains of erectile function.

Safety outcomes are also important because an ingredient can produce biological effects without providing a favorable overall benefit-risk profile. Studies may monitor adverse events, blood pressure, laboratory measurements, medication interactions, and treatment discontinuation.

Research on horny goat weed for erectile dysfunction can use randomized controlled designs, standardized extracts, validated erectile-function questionnaires, and safety monitoring to determine whether treatment produces clinically meaningful benefits beyond placebo effects.

Clinical Studies of Horny Goat Weed for Erectile Dysfunction Treatment

Clinical evidence for horny goat weed in erectile dysfunction is limited, and most human studies have evaluated Epimedium as one ingredient in a multi-herb preparation rather than as a standardized horny goat weed extract. Recent reviews note that the available clinical studies are generally small, use different preparations, and do not provide the same level of evidence available for established ED treatments.

Cappra® Randomized Crossover Study

The 2013 Thai study evaluated Cappra®, a five-herb preparation containing 120 g of Epimedium Drevicornum Maxim along with deer antler, Cynomorium, safflower, and Cistanche. Sixty-three men with mild or mild-to-moderate ED entered the randomized, double-blind, placebo-controlled crossover study, with 61 completing it. Participants received Cappra or placebo for two weeks, followed by a one-week washout and crossover treatment.

The primary outcome was change in the International Index of Erectile Function (IIEF), and the erectile-function domain improved more with Cappra than placebo. The mean change was 4.87 versus 3.44 points, respectively, with a reported p value of 0.032. Adverse events included dizziness, facial numbness, and tachycardia. Because Cappra contained several active ingredients, the study cannot establish that Epimedium alone caused the observed effect.

Study: A Randomized, Double-Blind, Placebo-Controlled Crossover Study of Cappra®

VigRX Plus Randomized Controlled Study

A 2012 multicenter trial examined VigRX Plus, a 10-ingredient supplement that included Epimedium sagittatum leaf, in 78 men with mild-to-moderate ED. Participants received either VXP or placebo for 12 weeks in a randomized, double-blind design.

The primary outcome was IIEF, and the VXP group showed a significantly greater improvement in erectile-function scores than placebo. IIEF-EF increased from 16.08 to 25.08 in the treatment group compared with 15.86 to 16.47 with placebo, with p < 0.0001. Treatment satisfaction also improved, but the study could not separate the contribution of Epimedium from the other nine ingredients.

Study: Evaluation of a Multi-Herb Supplement for Erectile Dysfunction

Anhydroicaritin Homolog Clinical Study

A 2013 Chinese clinical study investigated an anhydroicaritin homolog derived from Epimedium in 20 men aged 50–70 years with moderate ED. The participants were divided into treatment and control groups, and the researchers assessed changes in erectile function before and after treatment.

The study used International Index of Erectile Function measurements as an outcome for evaluating erectile function. The publication reported clinical effects associated with the anhydroicaritin homolog, although the very small sample and limited study design make the findings difficult to interpret independently. The reported statistical evidence was also limited, with the review literature noting P > 0.05.

Study: Anhydroicaritin Homolog for Male Erectile Dysfunction

LEOPIN ROYAL Clinical Trial

A Japanese randomized clinical study followed 49 aging men for six months while comparing LEOPIN ROYAL with traditional Kampo treatment, with Epimedium included among the natural ingredients in LEOPIN ROYAL. The preparation also contained aged garlic extract, ginseng, velvet antler, cuscuta seed, and other components, so it was not a test of horny goat weed alone.

Researchers measured the Aging Males’ Symptoms scale, IIEF-5, Androgen Deficiency in the Aging Male questionnaire, and depression-related symptoms. The study did not demonstrate a clear between-group difference in sexual-function changes, testosterone, FSH, LH, or estradiol, which provides weaker support for an independent ED effect from Epimedium.

Study: Improvement of Symptoms of Aging in Males by LEOPIN ROYAL

Koryo Medicine Study of Psychogenic Impotence

A 2026 clinical report evaluated an “Impotence capsule” containing Epimedium together with mulberry root, safflower, Achyranthes, Ginkgo, and jujube in patients with psychogenic impotence. Participants received the preparation three times daily for 20 days, while researchers assessed penile erection, clinical symptoms, sperm count, and sperm motility.

The authors reported improved penile erection and clinical symptoms, together with changes in semen-related measures, but the preparation contained multiple herbs and the published report provides limited methodological detail. Therefore, these findings cannot establish an independent effect of horny goat weed.

Study: Experimental and Clinical Studies on the Rapid Erectile Effect of Koryo Medicine

What the Clinical Evidence Shows

Taken together, human studies provide preliminary signals of possible benefit but do not establish horny goat weed as an effective standalone treatment for erectile dysfunction. The strongest controlled studies involving Epimedium tested combination products, while direct research on standardized Epimedium extracts or isolated icariin remains sparse. Recent clinical reviews therefore continue to describe the evidence as limited and call for larger, well-controlled trials using standardized preparations and validated erectile-function outcomes.

Clinical studies involving horny goat weed have reported improvements in some measures of erectile function, particularly IIEF scores, but most tested multi-ingredient products rather than Epimedium alone. The available evidence supports further investigation rather than a firm conclusion that horny goat weed independently treats erectile dysfunction.

Limitations of Existing Research on Horny Goat Weed

Limited Number of Direct Clinical Trials

The main limitation of research on horny goat weed for erectile dysfunction is the small amount of high-quality human evidence available. Much of the research on Epimedium and its compounds comes from laboratory or animal studies rather than large randomized clinical trials involving men with diagnosed erectile dysfunction.

Several human studies have investigated products containing Epimedium together with multiple other herbal ingredients. When participants experience an improvement, researchers cannot determine how much of the effect came from horny goat weed, another ingredient, or interactions between ingredients.

Differences Between Herbal Preparations

Commercial horny goat weed products can differ substantially in their Epimedium species, extraction methods, and concentrations of icariin and other compounds. This variation makes it difficult to compare results across studies or determine whether findings from one preparation apply to another.

Important sources of variation include:

• Epimedium species and plant material used
• Icariin concentration
• Extraction and manufacturing methods
• Dosage and treatment duration
• Combination with other herbal ingredients
• Product standardization and quality control

Small Samples and Short Follow-Up

Some available clinical studies involve relatively small numbers of participants and short treatment periods. Small samples reduce statistical power and make it harder to identify uncommon adverse effects or determine whether observed improvements are consistent across different populations.

Short follow-up periods also provide limited information about long-term effectiveness and safety. Erectile dysfunction is often a chronic condition, so studies lasting only several weeks may not show whether benefits persist with continued use.

Outcome and Study-Design Issues

Studies have used different measures of erectile function, which can make direct comparisons difficult. Although validated tools such as the IIEF can provide useful patient-reported outcomes, some studies rely on broader assessments of sexual function or clinical symptoms.

Future research would benefit from larger randomized, double-blind, placebo-controlled trials using standardized Epimedium extracts and clearly defined icariin concentrations. Longer follow-up and consistent erectile-function measures would also improve the quality of evidence.

Research on horny goat weed for erectile dysfunction is limited by small studies, short follow-up, variable preparations, and frequent use of multi-ingredient products, leaving uncertainty about the independent clinical effects of Epimedium.

Summary of Clinical Studies of Horny Goat Weed for Erectile Dysfunction

Current Evidence

Clinical research on horny goat weed for erectile dysfunction provides some evidence of potential benefit, but the available findings do not establish a consistent effect from horny goat weed as a standalone treatment. Several human studies have reported improvements in erectile-function measures after using preparations that contain Epimedium, particularly products that also contain other herbal ingredients.

The most frequently reported outcome is an improvement in scores from validated erectile-function questionnaires such as the International Index of Erectile Function. However, positive findings from multi-ingredient products cannot be attributed specifically to horny goat weed because the other ingredients may also affect sexual function.

Findings From Clinical Research

Controlled clinical research has produced mixed results, with some studies reporting improvements in erectile function and another study failing to demonstrate clear between-group differences in sexual outcomes. This variation may reflect differences in participant characteristics, product composition, treatment duration, dosage, and study design.

The existing research has generally examined:

• IIEF and IIEF-5 scores
• Erectile quality and sexual performance
• Sexual satisfaction
• General symptoms associated with sexual dysfunction
• Sperm-related outcomes in some studies
• Adverse events and treatment tolerability

Research on icariin and Epimedium extracts also provides a biological rationale for further investigation because experimental studies suggest effects on nitric oxide signaling, smooth-muscle relaxation, and PDE5-related pathways. These mechanisms are relevant to erectile physiology, but laboratory activity does not demonstrate that an oral supplement will produce a clinically meaningful improvement in men.

Overall Interpretation

The current clinical evidence should therefore be considered preliminary rather than conclusive. The strongest limitation is the lack of large, well-controlled trials that evaluate a standardized horny goat weed preparation by itself in men with clearly defined erectile dysfunction.

Future studies should use standardized Epimedium extracts, clearly report icariin content, include larger participant groups, use placebo controls, and measure validated erectile-function outcomes over longer periods. Such research could clarify whether horny goat weed has an independent therapeutic effect and identify appropriate doses and patient populations.

Clinical studies suggest that some Epimedium-containing preparations may improve measures of erectile function, but current evidence is insufficient to establish horny goat weed as an effective standalone treatment for erectile dysfunction.